Advertisement

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial

Published:March 05, 2016DOI:https://doi.org/10.1016/j.jhep.2016.02.042

      Background & Aims

      The new pan-genotypic regimen [sofosbuvir (SOF) and velpatasvir (VEL)] for hepatitis C virus (HCV) has been associated with high efficacy. The aim of this study was to assess patient-reported outcomes (PROs) of this regimen.

      Methods

      The PRO data (CLDQ-HCV, SF-36, FACIT-F, WPAI) came from the ASTRAL-1 study, a multicenter multinational blinded placebo-controlled phase 3 clinical trial of a fixed dose combination of SOF 400 mg and VEL 100 mg for patients with genotype 1, 2, 4, 5, and 6 compared to placebo for 12 weeks.

      Results

      624 patients received active treatment [618 achieved sustained virologic response (SVR)], and 116 received placebo. The baseline PRO scores were similar. By treatment week 4, patients receiving SOF/VEL experienced improvements in general health (on average, +2.3 points), emotional well-being (+3.4), FACIT-F (+1.3), and all domains of CLDQ-HCV (+2.1 to +7.3) (all p <0.005). On the other hand, the only PRO that improved in patients receiving placebo was the worry domain of CLDQ-HCV: +4.6 (p = 0.002). By the end of treatment, improvement in PRO scores with SOF/VEL continued, and no improvement was noted in the placebo. Improvement in PROs were also noted 12 and 24 weeks post-treatment: +3.7, on average, in patients with SVR-12 after SOF/VEL vs. −2.6, on average, in the placebo arm (p <0.005). Multivariate analysis showed that treatment-emergent changes in PROs were predicted by receiving SOF/VEL for some summary PRO score (p <0.005).

      Conclusions

      This placebo-controlled trial shows that patients treated with SOF/VEL experience significant improvement of their PROs during treatment and after achieving SVR.

      Lay summary

      In patients with chronic hepatitis C infection, health-related quality of life and work productivity are often impaired due to HCV-related fatigue. Treatment of hepatitis C with interferon-based regimens, which was the standard of care for all HCV patients until recently, had substantial and potentially debilitating side effects. These regimens caused additional impairment in health-related quality of life and work productivity during treatment and shortly after treatment cessation. The newly developed interferon-free combination of sofosbuvir and velpatasvir has been shown to improve health-related quality of life during treatment, and lead to an improvement in a number of indicators of patient-reported outcomes after successful clearance of HCV and achieving sustained virologic response.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Centers for Disease Control and Prevention (CDC).
        MMWR Morb Mortal Wkly Rep. 2012; 61: 1-18
        • Moyer V.A.
        • U.S. Preventive Services Task Force
        Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2013; 159: 349-357
        • Davis G.L.
        • Alter M.J.
        • El-Serag H.
        • Poynard T.
        • Jennings L.W.
        Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.
        Gastroenterology. 2010; 138: 513-521
        • El-Serag H.B.
        Epidemiology of viral hepatitis and hepatocellular carcinoma.
        Gastroenterology. 2012; 142 (e1): 1264-1273
        • Stepanova M.
        • Wai H.
        • Saab S.
        • Mishra A.
        • Venkatesan C.
        • Younossi Z.M.
        The portrait of an adult liver transplant recipient in the United States from 1987 to 2013.
        JAMA Intern Med. 2014; 174: 1407-1409
        • Jacobson I.M.
        • Cacoub P.
        • Dal Maso L.
        • Harrison S.A.
        • Younossi Z.M.
        Manifestations of chronic hepatitis C virus infection beyond the liver.
        Clin Gastroenterol Hepatol. 2010; 8: 1017-1029
        • Younossi Z.M.
        • Kanwal F.
        • Saab S.
        • Brown K.A.
        • El-Serag H.B.
        • Kim W.R.
        • et al.
        The impact of hepatitis C burden: an evidence-based approach.
        Aliment Pharmacol Ther. 2014; 39: 518-531
        • Razavi H.
        • Elkhoury A.C.
        • Elbasha E.
        • Estes C.
        • Pasini K.
        • Poynard T.
        • et al.
        Chronic hepatitis C virus (HCV) disease burden and cost in the United States.
        Hepatology. 2013; 57: 2164-2170
        • Spiegel B.M.
        • Younossi Z.M.
        • Hays R.D.
        • Revicki D.
        • Robbins S.
        • Kanwal F.
        Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment.
        Hepatology. 2005; 41: 790-800
        • Kallman J.
        • O’Neil M.M.
        • Larive B.
        • Boparai N.
        • Calabrese L.
        • Younossi Z.M.
        Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection.
        Dig Dis Sci. 2007; 52: 2531-2539
        • Kleinman L.
        • Mannix S.
        • Yuan Y.
        • Kummer S.
        • L’Italien G.
        • Revicki D.
        Review of patient-reported outcome measures in chronic hepatitis C.
        Health Qual Life Outcomes. 2012; 7: 92
        • Younossi Z.M.
        • Stepanova M.
        • Henry L.
        • Gane E.
        • Jacobson I.M.
        • Lawitz E.
        • et al.
        Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
        J Hepatol. 2014; 60: 741-747
        • Younossi Z.M.
        • Stepanova M.
        • Henry L.
        • Gane E.
        • Jacobson I.M.
        • Lawitz E.
        • et al.
        Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.
        Clin Gastroenterol Hepatol. 2014; 12 (e13): 1349-1359
        • Younossi Z.
        • Kallman J.
        • Kincaid J.
        The effects of HCV infection and management on health-related quality of life.
        Hepatology. 2007; 45: 806-816
        • McHutchison J.G.
        • Ware Jr, J.E.
        • Bayliss M.S.
        • Pianko S.
        • Albrecht J.K.
        • Cort S.
        • et al.
        • Hepatitis Interventional Therapy Group
        The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.
        J Hepatol. 2001; 34: 140-147
        • Younossi Z.M.
        • Stepanova M.
        • Henry L.
        • Nader F.
        • Hunt S.L.
        Interferon (IFN), Ribavirin (RBV), duration of treatment and baseline Patient-Reported Outcomes (PROs) predict adherence to the new regimens for treatment of Chronic Hepatitis C (CH-C).
        Hepatology. 2015; 62: 371A
        • Younossi Z.
        • Henry L.
        Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens.
        Aliment Pharmacol Ther. 2015; 41 ([Epub 2015 Jan 23. Review]): 497-520https://doi.org/10.1111/apt.13090
        • Younossi Z.M.
        • Stepanova M.
        • Henry L.
        • Nader F.
        • Hunt S.
        An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens.
        Am J Gastroenterol. 2016; ([Epub ahead of print])https://doi.org/10.1038/ajg.2016.99
        • Zeuzem S.
        • Dusheiko G.M.
        • Salupere R.
        • Mangia A.
        • Flisiak R.
        • Hyland R.H.
        • et al.
        Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
        N Engl J Med. 2014; 370: 1993-2001
        • Andreone P.
        • Colombo M.G.
        • Enejosa J.V.
        • Koksal I.
        • Ferenci P.
        • Maieron A.
        • et al.
        ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
        Gastroenterology. 2014; 147 (PEARL II): 359-365
        • Poordad F.
        • Hezode C.
        • Trinh R.
        • Kowdley K.V.
        • Zeuzem S.
        • Agarwal K.
        • et al.
        ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
        N Engl J Med. 2014; 370 (TURQUOISE II): 1973-1982
        • Zeuzem S.
        • Jacobson I.M.
        • Baykal T.
        • Marinho R.T.
        • Poordad F.
        • Bourlière M.
        • et al.
        Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
        N Engl J Med. 2014; 370 (SAPPHIRE II): 1604-1614
        • Lawitz E.
        • Sulkowski M.S.
        • Ghalib R.
        • Rodriguez-Torres M.
        • Younossi Z.M.
        • Corregidor A.
        • et al.
        Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
        Lancet. 2014; 384: 1756-1765
        • Afdhal N.
        • Zeuzem S.
        • Kwo P.
        • Chojkier M.
        • Gitlin N.
        • Puoti M.
        • et al.
        Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
        N Engl J Med. 2014; 370: 1889-1898
        • Afdhal N.
        • Reddy K.R.
        • Nelson D.R.
        • Lawitz E.
        • Gordon S.C.
        • Schiff E.
        • et al.
        Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
        N Engl J Med. 2014; 370: 1483-1493
        • Kowdley K.V.
        • Gordon S.C.
        • Reddy K.R.
        • Rossaro L.
        • Bernstein D.E.
        • Lawitz E.
        • et al.
        Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
        N Engl J Med. 2014; 370: 1879-1888
        • Nelson D.R.
        • Cooper J.N.
        • Lalezari J.P.
        • Lawitz E.
        • Pockros P.J.
        • Gitlin N.
        • et al.
        All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
        Hepatology. 2015; 61: 1127-1135
        • Smith M.A.
        • Regal R.E.
        • Mohammad R.A.
        Daclatasvir: A NS5A replication complex inhibitor for hepatitis C infection.
        Ann Pharmacother. 2016; 50: 39-46
        • Younossi Z.M.
        • Stepanova M.
        • Henry L.
        • Gane E.
        • Jacobson I.M.
        • Lawitz E.
        • et al.
        Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.
        Clin Gastroenterol Hepatol. 2014; 12 (e13): 1349-1359
        • Younossi Z.M.
        • Stepanova M.
        • Zeuzem S.
        • Dusheiko G.
        • Esteban R.
        • Hezode C.
        • et al.
        Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
        J Hepatol. 2014; 61: 228-234
        • Younossi Z.M.
        • Stepanova M.
        • Nader F.
        • Jacobson I.M.
        • Gane E.
        • Nelson D.
        • et al.
        Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
        Hepatology. 2014; 59: 2161-2169
        • Younossi Z.M.
        • Stepanova M.
        • Afdhal N.
        • Kowdley K.V.
        • Zeuzem S.
        • Henry L.
        • et al.
        Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
        J Hepatol. 2015; 63: 337-345
        • Younossi Z.M.
        • Stepanova M.
        • Pol S.
        • Bronowicki J.P.
        • Carrieri M.P.
        • Bourlière M.
        The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
        Liver Int. 2016; 36: 42-48
        • Younossi Z.M.
        • Stepanova M.
        • Sulkowski M.
        • Naggie S.
        • Puoti M.
        • Orkin C.
        • et al.
        Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes.
        J Infect Dis. 2015; 212: 367-377
        • Younossi Z.M.
        • Stepanova M.
        • Marcellin P.
        • Afdhal N.
        • Kowdley K.V.
        • Zeuzem S.
        • et al.
        Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials.
        Hepatology. 2015; 61: 1798-1808
        • Younossi Z.M.
        • Stepanova M.
        • Nader F.
        • Lam B.
        • Hunt S.
        The patient’s journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.
        Aliment Pharmacol Ther. 2015; 42: 286-295
        • Vera-Llonch M.
        • Martin M.
        • Aggarwal J.
        • Donepudi M.
        • Bayliss M.
        • Goss T.
        • et al.
        Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study.
        Aliment Pharmacol Ther. 2013; 38: 124-133
        • Aggarwal J.
        • Vera-Llonch M.
        • Donepudi M.
        • Suthoff E.
        • Younossi Z.
        • Goss T.F.
        Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment.
        J Viral Hepat. 2015; 22: 8-17
        • Younossi Z.
        • Henry L.
        Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens.
        Aliment Pharmacol Ther. 2015; 41: 497-520
        • Redelmeier D.A.
        • Dickinson V.M.
        Determining whether a patient is feeling better: pitfalls from the science of human perception.
        J Gen Intern Med. 2011; 26: 900-906
        • Feld J.J.
        • Jacobson I.M.
        • Hézode C.
        • Asselah T.
        • Ruane P.J.
        • Gruener N.
        • et al.
        Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.
        N Engl J Med. 2015; 373: 2599-2607
        • Ware J.E.
        • Kosinski M.
        Interpreting SF-36 summary health measures: a response.
        Qual Life Res. 2001; 10: 405-413
        • Webster K.
        • Odom L.
        • Peterman A.
        • Lent L.
        • Cella D.
        The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire.
        Qual Life Res. 1999; 8: 604
        • Younossi Z.M.
        • Guyatt G.
        • Kiwi M.
        • Boparai N.
        • King D.
        Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease.
        Gut. 1999; 45: 295-300
        • Reilly M.C.
        • Zbrozek A.S.
        • Dukes E.M.
        The validity and reproducibility of a work productivity and activity impairment instrument.
        Pharmacoeconomics. 1993; 4: 353-365
        • Gerber L.
        • Estep M.
        • Stepanova M.
        • Escheik C.
        • Weinstein A.
        • Younossi Z.M.
        Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection.
        Clin Gastroenterol Hepatol. 2016; 14 (e3): 156-164
        • Monaco S.
        • Mariotto S.
        • Ferrari S.
        • Calabrese M.
        • Zanusso G.
        • Gajofatto A.
        • et al.
        Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015.
        World J Gastroenterol. 2015; 21: 11974-11983
        • Byrnes V.
        • Miller A.
        • Lowry D.
        • Hill E.
        • Weinstein C.
        • Alsop D.
        • et al.
        Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
        J Hepatol. 2012; 56: 549-556
        • Two R.
        • Verjee-Lorenz A.
        • Clayson D.
        • Dalal M.
        • Grotzinger K.
        • Younossi Z.M.
        A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries.
        Value Health. 2010; 13: 128-131